<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20110310165527+01'00'</creation_date><modification_date>D:20110310165530+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_dec_37.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission brussels, 28.2.2011 c(2011)1489</p></section><section><header>commission decision of 28.2.2011 
 amending the marketing authorisation granted by decision c(2000)1407 for 
 “pegintron - peginterferon alfa-2b”, a medicinal product for human use</header><p>(only the french and dutch texts are authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 28.2.2011 
 amending the marketing authorisation granted by decision c(2000)1407 for 
 “pegintron - peginterferon alfa-2b”, a medicinal product for human use 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 20(7)(a) thereof, 
 having regard to the application submitted on 21 november 2010 by schering plough 
 europe under article 20(3) of regulation (ec) no 1234/2008, 
 having regard to the opinion of the european medicines agency, formulated on 20 
 january 2011 by the committee for medicinal products for human use, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the minor variation of 
 type ib and of the need to amend the marketing authorisation. 
 (2)</p><p>the marketing authorisation should be updated and decision c(2000)1407 of 25 
 may 2000 should therefore be amended accordingly. the community register of 
 medicinal products should also be updated. 
 (3)</p><p>for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2000)1407 should therefore be replaced,</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>has adopted this decision: article 1 decision c(2000)1407 is amended as follows: annex i is replaced by the text set out in the annex i to this decision. 
 article 2 this decision is addressed to schering plough europe, rue de stalle, 73, 1180 bruxelles, belgique - stallestraat, 73 - 1180 brussel, belgië. 
 done at brussels, on 28.2.2011.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>